| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H8ClF6NO2 |
| Molecular Weight | 383.673 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(Cl)C=C1C(=O)NC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F
InChI
InChIKey=CHILCFMQWMQVAL-UHFFFAOYSA-N
InChI=1S/C15H8ClF6NO2/c16-9-1-2-12(24)11(6-9)13(25)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6,24H,(H,23,25)
| Molecular Formula | C15H8ClF6NO2 |
| Molecular Weight | 383.673 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
IMD-0354 is an inhibitor of IκB kinase-β (IKKβ) that blocks NF-κB nuclear translocation. Attenuates myocardial ischemia/reperfusion injury by decreasing expression of adhesion molecules ICAM-1 and P-selectin and inhibiting cytokine and chemokine production in cardiomyocytes. Induces G0/G1 cell cycle arrest and apoptosis in HMC-1 and breast cancer cells. IMD-0354 had been in phase I clinical trials for the treatment of atopic dermatitis.
Originator
Approval Year
Sourcing
PubMed
Sample Use Guides
1, 5, or 10 mg/kg intraperitoneal injection in a single bolus 5 min before the start of reperfusion.
Route of Administration:
Other
|
|
TARGET -> INHIBITOR |
IC50
740 NANOMOLAR (average) |
Showing 1 to 1 of 1 entries
